CD34 and neoplasm: Another commonly used approach is to produce DCs from CD34+ hematopoietic stem and progenitor cells (HSPCs) (21, 22), which have an extensive proliferation capacity to generate antigen presenting cells (APCs) with a primary DC phenotype (23) and the capacity to induce robust anti-tumor T cell responses.